Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:CLLS NASDAQ:GALT NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.02$1.88$0.51▼$2.66$271.82M0.421.67 million shs428,201 shsCLLSCellectis$2.77-1.1%$3.14$2.00▼$5.48$280.95M2.8819,436 shs8,946 shsGALTGalectin Therapeutics$3.45-1.4%$3.34$2.03▼$7.13$230.50M0.351.05 million shs335,090 shsMNOVMediciNova$1.31-1.5%$1.35$1.17▼$1.96$65.46M0.6259,564 shs33,785 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology0.00%-2.42%+14.77%+20.96%+299.05%CLLSCellectis-1.07%+3.75%-4.48%-28.79%+18.88%GALTGalectin Therapeutics-1.43%-18.25%+10.58%+48.07%+22.34%MNOVMediciNova-1.50%-7.75%-3.68%-4.38%+4.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.02$1.88$0.51▼$2.66$271.82M0.421.67 million shs428,201 shsCLLSCellectis$2.77-1.1%$3.14$2.00▼$5.48$280.95M2.8819,436 shs8,946 shsGALTGalectin Therapeutics$3.45-1.4%$3.34$2.03▼$7.13$230.50M0.351.05 million shs335,090 shsMNOVMediciNova$1.31-1.5%$1.35$1.17▼$1.96$65.46M0.6259,564 shs33,785 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology0.00%-2.42%+14.77%+20.96%+299.05%CLLSCellectis-1.07%+3.75%-4.48%-28.79%+18.88%GALTGalectin Therapeutics-1.43%-18.25%+10.58%+48.07%+22.34%MNOVMediciNova-1.50%-7.75%-3.68%-4.38%+4.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.67Moderate Buy$4.60127.72% UpsideCLLSCellectis 2.83Moderate Buy$7.00152.71% UpsideGALTGalectin Therapeutics 1.67Reduce$11.00218.84% UpsideMNOVMediciNova 2.67Moderate Buy$8.33536.13% UpsideCurrent Analyst Ratings BreakdownLatest MNOV, GALT, CLLS, and ALXO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026GALTGalectin Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/26/2026ALXOALX Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026MNOVMediciNova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026GALTGalectin Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.006/18/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026MNOVMediciNova D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 7/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/ACLLSCellectis$79.59M3.49N/AN/A$0.76 per share3.64GALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/AMNOVMediciNova$410K157.26N/AN/A$0.85 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%8/11/2026 (Estimated)CLLSCellectis-$67.59M-$0.67N/AN/AN/A-89.51%-80.66%-20.51%7/30/2026 (Estimated)GALTGalectin Therapeutics-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)MNOVMediciNova-$12M-$0.23N/AN/AN/A-1,962.98%-27.28%-25.24%8/13/2026 (Estimated)Latest MNOV, GALT, CLLS, and ALXO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026GALTGalectin Therapeutics-$0.09N/AN/AN/AN/AN/A8/13/2026Q2 2026MNOVMediciNova-$0.06N/AN/AN/A$0.08 millionN/A8/11/2026Q2 2026ALXOALX Oncology-$0.15N/AN/AN/AN/AN/A8/11/2026H1 2026CLLSCellectis-$0.2630N/AN/AN/A$11.05 millionN/A5/15/2026Q1 2026GALTGalectin Therapeutics-$0.06-$0.08-$0.02-$0.08N/AN/A5/14/2026Q1 2026MNOVMediciNova-$0.06-$0.05+$0.01-$0.05$0.19 million$0.19 million5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 million$7.55 million5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.027.217.21CLLSCellectis1.131.521.52GALTGalectin TherapeuticsN/A2.152.15MNOVMediciNovaN/A9.099.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%CLLSCellectis63.90%GALTGalectin Therapeutics11.68%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%CLLSCellectis16.41%GALTGalectin Therapeutics52.60%MNOVMediciNova14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology40134.56 million106.31 millionOptionableCLLSCellectis290100.34 million83.87 millionOptionableGALTGalectin Therapeutics965.86 million31.22 millionOptionableMNOVMediciNova1049.22 million42.33 millionOptionableMNOV, GALT, CLLS, and ALXO HeadlinesRecent News About These CompaniesMediciNova, Inc. (NASDAQ:MNOV) Sees Significant Increase in Short InterestJuly 16, 2026 | marketbeat.comMediciNova Achieves Full Enrollment in NIH-Funded SEANOBI-ALS Study of MN-166 (Ibudilast) for ALSJuly 15, 2026 | quiverquant.comQMediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsJuly 15, 2026 | globenewswire.comMediciNova CEO Provides Shareholder UpdateJune 30, 2026 | globenewswire.comMediciNova Shareholders Reject Proposal to Increase Authorized StockJune 24, 2026 | tipranks.comMNOV Share News TodayJune 21, 2026 | uk.investing.comMediciNova (MNOV) Stock Forecast & Price TargetJune 11, 2026 | investing.comMediciNova, Inc.: MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentJune 8, 2026 | finanznachrichten.deMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentJune 8, 2026 | globenewswire.comMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical ...May 26, 2026 | caledonianrecord.comCMediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes May 26, 2026 | quiverquant.comQMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)May 26, 2026 | globenewswire.comMediciNova Announces New Insights on Brain Metastasis Vulnerability and Potential Therapeutic Strategies from CNIO StudyApril 27, 2026 | quiverquant.comQNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationApril 27, 2026 | globenewswire.comHC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendationMarch 17, 2026 | msn.comMediciNova to Participate at the 38th Annual ROTH ConferenceMarch 16, 2026 | globenewswire.comMediciNova: Q4 Earnings SnapshotFebruary 20, 2026 | wtop.comWMediciNova (MNOV) price target increased by 28.57% to 9.18February 4, 2026 | msn.comMediciNova Reports 100 Patient Enrollment in SEANOBI Study for MN-166 (Ibudilast) in ALS TreatmentJanuary 29, 2026 | quiverquant.comQMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsJanuary 29, 2026 | globenewswire.comMediciNova, Inc.: 2026 New Year's Greetings from the CEOJanuary 7, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNOV, GALT, CLLS, and ALXO Company DescriptionsALX Oncology NASDAQ:ALXO$2.02 0.00 (0.00%) Closing price 07/23/2026 04:00 PM EasternExtended Trading$2.04 +0.02 (+0.74%) As of 07/23/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Cellectis NASDAQ:CLLS$2.77 -0.03 (-1.07%) Closing price 07/23/2026 04:00 PM EasternExtended Trading$2.78 +0.01 (+0.36%) As of 07/23/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Galectin Therapeutics NASDAQ:GALT$3.45 -0.05 (-1.43%) As of 07/23/2026 04:00 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.MediciNova NASDAQ:MNOV$1.31 -0.02 (-1.50%) Closing price 07/23/2026 04:00 PM EasternExtended Trading$1.34 +0.03 (+2.21%) As of 07/23/2026 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Alphabet Crushed Earnings, But One Number Spooked the Market Premium Retail’s Stress Test Is Separating Winners From Losers GE Vernova Just Sent a Mixed AI Signal to Investors Otis Took Another Guidance Cut—But the Story Isn't Over Philip Morris Trimmed Guidance, But Its Growth Story Looks Unshaken The 2026 Blueprint: 6 Stocks for a Brand New Portfolio Cementing the Sky: Why NVIDIA’s Bet on Nebius Matters Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
